Shanghai Fosun Pharmaceutical's (Group) (HKG:2196, SHA:600196) subsidiary Fosun Adgenvax (Chengdu) Biopharmaceutical obtained the National Medical Products Administration's approval for clinical trials for its 24-valent pneumococcal polysaccharide conjugate vaccine, a Tuesday bourse filing said.
Fosun Adgenvax (Chengdu) Biopharmaceutical plans to start the first phase of clinical trials in China.
The vaccine is a preventive biological product used for the prevention of certain infectious diseases caused by certain pneumococcal serotypes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。